nach oben

Current Hypertension Reports

Erschienen in:

09.11.2022 | Hypertension and the Heart (B Upadhya, Section Editor)

Hypertension Across a Woman’s Life Cycle

verfasst von: Lama Ghazi, Rahul V. Annabathula, Natalie A. Bello, Li Zhou, Richard Brandon Stacey, Bharathi Upadhya

Erschienen in: Current Hypertension Reports | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We reviewed the effects of hypertension and the means to prevent and treat it across the spectrum of a woman’s lifespan and identified gaps in sex-specific mechanisms contributing to hypertension in women that need to be addressed.

Recent Findings

Hypertension continues to be an important public health problem for women across all life stages from adolescence through pregnancy, menopause, and older age. There remain racial, ethnic, and socioeconomic differences in hypertension rates not only overall but also between the sexes. Blood pressure cutoffs during pregnancy have not been updated to reflect the 2017 ACC/AHA changes due to a lack of data. Additionally, the mechanisms behind hypertension development in menopause, including sex hormones and genetic factors, are not well understood.

Summary

In the setting of increasing inactivity and obesity, along with an aging population, hypertension rates are increasing in women. Screening and management of hypertension throughout a women’s lifespan are necessary to reduce the burden of cardiovascular disease, and further research to understand sex-specific hypertension mechanisms is needed.

Hypertension. Key facts. 13 September 2019 [website]. https://www.who.int/news-room/fact-sheets/detail/hypertension. Accessed 15 Sept 2022.

Collaborators GRF. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1923–94.CrossRef

Centers for Disease Control and Prevention. Hypertension cascade: hypertension prevalence, treatment and control estimates among U.S. adults aged 18 years and older applying the criteria from the American College of Cardiology and American Heart Association’s 2017 Hypertension Guideline—NHANES 2015–2018. Atlanta, GA: U.S. Department of Health and Human Services; 2021. https://www.cdc.gov/bloodpressure/facts.htm. Accessed 15 Sept 2022.

Bennett A, Parto P, Krim SR. Hypertension and ethnicity. Curr Opin Cardiol. 2016;31:381–6.PubMedCrossRef

Zhao B, Jose PO, Pu J, Chung S, Ancheta IB, Fortmann SP, et al. Racial/ethnic differences in hypertension prevalence, treatment, and control for outpatients in northern california 2010–2012. Am J Hypertens. 2015;28:631–9.PubMedCrossRef

de Munter JS, Agyemang C, van Valkengoed IG, Bhopal R, Stronks K. Sex difference in blood pressure among South Asian diaspora in Europe and North America and the role of BMI: a meta-analysis. J Hum Hypertens. 2011;25:407–17.PubMedCrossRef

Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441–50.PubMedPubMedCentralCrossRef

Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in china: data from 1·7 million adults in a population-based screening study (china peace million persons project). Lancet. 2017;390:2549–58.PubMedCrossRef

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Subcommittee AHASCaSS: Heart disease and stroke statistics–2015 update: a report from the american heart association. Circulation. 2015;131:e29-322.PubMed

10.

Gerdts E, Okin PM, de Simone G, Cramariuc D, Wachtell K, Boman K, et al. Gender differences in left ventricular structure and function during antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension study. Hypertension. 2008;51:1109–14.PubMedCrossRef

11.

Gerdts E, Izzo R, Mancusi C, Losi MA, Manzi MV, Canciello G, et al. Left ventricular hypertrophy offsets the sex difference in cardiovascular risk (the campania salute network). Int J Cardiol. 2018;258:257–61.PubMedCrossRef

12.

Patel SA, Winkel M, Ali MK, Narayan KM, Mehta NK. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann Intern Med. 2015;163:245–53.PubMedCrossRef

13.

Falkstedt D, Koupil I, Hemmingsson T. Blood pressure in late adolescence and early incidence of coronary heart disease and stroke in the Swedish 1969 conscription cohort. J Hypertens. 2008;26:1313–20.PubMedCrossRef

14.

Högström G, Nordström A, Eriksson M, Nordström P. Risk factors assessed in adolescence and the later risk of stroke in men: a 33-year follow-up study. Cerebrovasc Dis. 2015;39:63–71.PubMedCrossRef

15.

Dost A, Bechtold S, Fink K, Bonfig W, Wiemann D, Kapellen TM, et al. Center iD-SatGDR: 2017 American Academy Of Pediatrics Clinical Practice guideline: impact on prevalence of arterial hypertension in children and adolescents with type 1 diabetes. Diabetes Care. 2020;43:1311–8.PubMedCrossRef

16.

Al Kibria GM, Swasey K, Sharmeen A, Day B. Estimated change in prevalence and trends of childhood blood pressure levels in the United States after application of the 2017 AAP guideline. Prev Chronic Dis. 2019;16:E12.PubMedPubMedCentralCrossRef

17.

Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40:441–7.PubMedCrossRef

18.

Falkner B, Gidding SS, Ramirez-Garnica G, Wiltrout SA, West D, Rappaport EB. The relationship of body mass index and blood pressure in primary care pediatric patients. J Pediatr. 2006;148:195–200.PubMedCrossRef

19.

Archbold KH, Vasquez MM, Goodwin JL, Quan SF. Effects of sleep patterns and obesity on increases in blood pressure in a 5-year period: report from the Tucson children’s assessment of sleep apnea study. J Pediatr. 2012;161:26–30.PubMedPubMedCentralCrossRef

20.

Grandi AM, Gaudio G, Fachinetti A, Bianchi L, Nardo B, Zanzi P, et al. Hyperinsulinemia, family history of hypertension, and essential hypertension. Am J Hypertens. 1996;9:732–8.PubMedCrossRef

21.

von Eiff AW, Gogolin E, Jacobs U, Neus H. Ambulatory blood pressure in children followed for 3 years. Influence of sex and family history of hypertension. Clin Exp Hypertens A. 1986;8:577–81.

22.

Munger RG, Prineas RJ, Gomez-Marin O. Persistent elevation of blood pressure among children with a family history of hypertension: the Minneapolis children’s blood pressure study. J Hypertens. 1988;6:647–53.PubMedCrossRef

23.

Cheung EL, Bell CS, Samuel JP, Poffenbarger T, Redwine KM, Samuels JA. Race and obesity in adolescent hypertension. Pediatrics. 2017;139.

24.

Ogunniyi MO, Commodore-Mensah Y, Ferdinand KC. Race, ethnicity, hypertension, and heart disease: Jacc focus seminar 1/9. J Am Coll Cardiol. 2021;78:2460–70.PubMedCrossRef

25.

Bolívar JJ. Essential hypertension: an approach to its etiology and neurogenic pathophysiology. Int J Hypertens. 2013;2013:547809.PubMedPubMedCentralCrossRef

26.

Chrysaidou K, Chainoglou A, Karava V, Dotis J, Printza N, Stabouli S. Secondary hypertension in children and adolescents: novel insights. Curr Hypertens Rev. 2020;16:37–44.PubMedCrossRef

27.

Hartung EA, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics. 2014;134:e833-845.PubMedPubMedCentralCrossRef

28.

Narula N, Kadian-Dodov D, Olin JW. Fibromuscular dysplasia: contemporary concepts and future directions. Prog Cardiovasc Dis. 2018;60:580–5.PubMedCrossRef

29.

Hendricks NJ, Matsumoto AH, Angle JF, Baheti A, Sabri SS, Park AW, et al. Is fibromuscular dysplasia underdiagnosed? A comparison of the prevalence of FMD seen in coral trial participants versus a single institution population of renal donor candidates. Vasc Med. 2014;19:363–7.PubMedCrossRef

30.

Poloskey SL, Olin JW, Mace P, Gornik HL. Fibromuscular dysplasia. Circulation. 2012;125:e636-639.PubMedCrossRef

31.

Bubach S, De Mola CL, Hardy R, Dreyfus J, Santos AC, Horta BL. Early menarche and blood pressure in adulthood: systematic review and meta-analysis. J Public Health (Oxf). 2018;40:476–84.PubMedCrossRef

32.

Wu CH, Chiu LT, Chang YJ, Lee CI, Lee MS, Lee TH, et al. Hypertension risk in young women with polycystic ovary syndrome: a nationwide population-based cohort study. Front Med (Lausanne). 2020;7:574651.PubMedCrossRef

33.

Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma Lancet. 2005;366:665–75.PubMedCrossRef

34.

Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287:1427–34.PubMedCrossRef

35.

Sybert VP, McCauley E. Turner’s syndrome. N Engl J Med. 2004;351:1227–38.PubMedCrossRef

36.

Lin AE, Prakash SK, Andersen NH, Viuff MH, Levitsky LL, Rivera-Davila M, et al. Recognition and management of adults with turner syndrome: from the transition of adolescence through the senior years. Am J Med Genet A. 2019;179:1987–2033.PubMedCrossRef

37.

Lacro RV, Jones KL, Benirschke K. Coarctation of the aorta in turner syndrome: a pathologic study of fetuses with nuchal cystic hygromas, hydrops fetalis, and female genitalia. Pediatrics. 1988;81:445–51.PubMed

38.

Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. 2008;117:3171–80.PubMedPubMedCentralCrossRef

39.

Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol. 2018;14:185–201.PubMedCrossRef

40.

Viera AJ, Neutze DM. Diagnosis of secondary hypertension: an age-based approach. Am Fam Physician. 2010;82:1471–8.PubMed

41.

Wenger NK, Arnold A, Bairey Merz CN, Cooper-DeHoff RM, Ferdinand KC, Fleg JL, et al. Hypertension across a woman’s life cycle. J Am Coll Cardiol. 2018;71:1797–813.PubMedPubMedCentralCrossRef

42.

Pappadis SL, Somers MJ. Hypertension in adolescents: a review of diagnosis and management. Curr Opin Pediatr. 2003;15:370–8.PubMedCrossRef

43.

Oparil S. Hypertension and oral contraceptives. J Cardiovasc Med. 1981;6(381):384–7.

44.

Bulletins—Gynecology. Acog practice bulletin no. 206: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019;133:e128–50.CrossRef

45.

Wang W, Xie X, Yuan T, Wang Y, Zhao F, Zhou Z, et al. Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels: a population-based study. BMC Pregnancy Childbirth. 2021;21:364.PubMedPubMedCentralCrossRef

46.

Program NHBPE. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Bbstet Gynecol. 2000;183(1):s1–s22.

47.

American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 202: gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133(1);e1–e25.

48.

Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S, et al. Management of hypertensive disorders during pregnancy: summary of nice guidance. BMJ. 2010;341:c2207.PubMedCrossRef

49.

Bernstein PS, Martin JN, Barton JR, Shields LE, Druzin ML, Scavone BM, et al. Consensus bundle on severe hypertension during pregnancy and the postpartum period. J Obstet Gynecol Neonatal Nurs. 2017;46:776–87.PubMedCrossRef

50.

Bulletins Obstetrics ACoOaGCoP. Acog practice bulletin no. 203: Chronic hypertension in pregnancy. Obstet Gynecol. 2019;133:e26–50.CrossRef

51.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 acc/aha/aapa/abc/acpm/ags/apha/ash/aspc/nma/pcna guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College Of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2018;138:e426–83.PubMed

52.

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 esc guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39:3165–241.PubMedCrossRef

53.

Butalia S, Audibert F, Côté AM, Firoz T, Logan AG, Magee LA, et al. Hypertension Canada’s 2018 guidelines for the management of hypertension in pregnancy. Can J Cardiol. 2018;34:526–31.PubMedCrossRef

54.

Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Group CHDoPW: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: Executive summary. J Obstet Gynaecol Can. 2014;36:416–41.PubMedCrossRef

55.

Boesen EI. Consequences of in-utero exposure to antihypertensive medication: the search for definitive answers continues. J Hypertens. 2017;35:2161–4.PubMedCrossRef

56.

Fitton CA, Steiner MFC, Aucott L, Pell JP, Mackay DF, Fleming M, et al. In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. J Hypertens. 2017;35:2123–37.PubMedPubMedCentralCrossRef

57.

Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ. 1999;318:1332–6.PubMedPubMedCentralCrossRef

58.

Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2019;2019.

59.

Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216:110-120.e116.PubMedCrossRef

60.

Euser AG, Cipolla MJ. Magnesium sulfate for the treatment of eclampsia: a brief review. Stroke. 2009;40:1169–75.PubMedPubMedCentralCrossRef

61.

•• Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for mild chronic hypertension during pregnancy. N Engl J Med. 2022. This article reports the results of a randomized controlled study on the effectiveness of treatment of mild chronic hypertension in pregnant women.

62.

Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:1404–23.PubMedPubMedCentralCrossRef

63.

Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, et al. Nursing CoCaS, Cardiology CoC, Prevention CoEa, Research CfHBP: guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1545–88.PubMedCrossRef

64.

Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010;56:166–71.PubMedCrossRef

65.

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Subcommittee AHASCaSS: Heart Disease and Stroke Statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.PubMedPubMedCentralCrossRef

66.

Martins D, Nelson K, Pan D, Tareen N, Norris K. The effect of gender on age-related blood pressure changes and the prevalence of isolated systolic hypertension among older adults: data from NHANES III. J Gend Specif Med. 2001;4(10–13):20.PubMed

67.

Staessen JA, Ginocchio G, Thijs L, Fagard R. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypertens. 1997;11:507–14.PubMedCrossRef

68.

Casiglia E, d’Este D, Ginocchio G, Colangeli G, Onesto C, Tramontin P, et al. Lack of influence of menopause on blood pressure and cardiovascular risk profile: a 16-year longitudinal study concerning a cohort of 568 women. J Hypertens. 1996;14:729–36.PubMedCrossRef

69.

Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007;14:373–84.PubMedCrossRef

70.

Meyer MR, Haas E, Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension. 2006;47:1019–26.PubMedCrossRef

71.

Levy D, DeStefano AL, Larson MG, O’Donnell CJ, Lifton RP, Gavras H, et al. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the Framingham Heart Study. Hypertension. 2000;36:477–83.PubMedCrossRef

72.

Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension. 2008;51:952–9.PubMedCrossRef

73.

Rana BK, Insel PA, Payne SH, Abel K, Beutler E, Ziegler MG, et al. Population-based sample reveals gene-gender interactions in blood pressure in White Americans. Hypertension. 2007;49:96–106.PubMedCrossRef

74.

Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, et al. Menopause is associated with endothelial dysfunction in women. Hypertension. 1996;28:576–82.PubMedCrossRef

75.

Rossi R, Chiurlia E, Nuzzo A, Cioni E, Origliani G, Modena MG. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. J Am Coll Cardiol. 2004;44:1636–40.PubMedCrossRef

76.

Pechère-Bertschi A, Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens. 2004;17:994–1001.PubMedCrossRef

77.

Moreau KL, Babcock MC, Hildreth KL. Sex differences in vascular aging in response to testosterone. Biol Sex Differ. 2020;11:18.PubMedPubMedCentralCrossRef

78.

DuPont JJ, Kenney RM, Patel AR, Jaffe IZ. Sex differences in mechanisms of arterial stiffness. Br J Pharmacol. 2019;176:4208–25.PubMedPubMedCentralCrossRef

79.

Gierach GL, Johnson BD, Bairey Merz CN, Kelsey SF, Bittner V, Olson MB, et al. Hypertension, menopause, and coronary artery disease risk in the women’s ischemia syndrome evaluation (wise) study. J Am Coll Cardiol. 2006;47:S50-58.PubMedCrossRef

80.

Oparil S. Women and hypertension: what did we learn from the women’s health initiative? Cardiol Rev. 2006;14:267–75.PubMedCrossRef

81.

Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:3975–4011.PubMedCrossRef

82.

Chiu CL, Lujic S, Thornton C, O’Loughlin A, Makris A, Hennessy A, et al. Menopausal hormone therapy is associated with having high blood pressure in postmenopausal women: Observational cohort study. PLoS ONE. 2012;7:e40260.PubMedPubMedCentralCrossRef

83.

• Madika AL, MacDonald CJ, Fournier A, Mounier-Vehier C, Béraud G, Boutron-Ruault MC. Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen administration and progestogens in the e3n cohort. Menopause. 2021;28:1204–8. This is an observational cohort study that assessed effect of different formulations of menopausal hormone therapy on incident hypertension among menopausal women.PubMedCrossRef

84.

• Yoon BK, Sung J, Song YM, Kim SM, Son KA, Yoo JH, et al. Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, placebo-controlled trial. Clin Hypertens. 2021;27:18. This was a randomized placebo controlled trial that assessed the impact of micronized progesterone combined estradiol gel on hemodynamics in postmenopausal women with grade 1 hypertension.PubMedPubMedCentralCrossRef

85.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Investigators WGftWsHI: risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288:321–33.PubMedCrossRef

86.

Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499–503.PubMedCrossRef

87.

Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT, et al. Potential us population impact of the 2017 acc/aha high blood pressure guideline. Circulation. 2018;137:109–18.PubMedCrossRef

88.

Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the association of the 2017 and 2014 hypertension guidelines with cardiovascular events and deaths in us adults: an analysis of national data. JAMA Cardiol. 2018;3:572–81.PubMedPubMedCentralCrossRef

89.

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Subcommittee AHACoEaPSCaSS: Heart Disease and Stroke Statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–528.PubMedCrossRef

90.

Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994;24:471–6.PubMedCrossRef

91.

Sandberg K, Ji H. Sex differences in primary hypertension. Biol Sex Differ. 2012;3:7.PubMedPubMedCentralCrossRef

92.

Elias PK, Elias MF, Robbins MA, Budge MM. Blood pressure-related cognitive decline: does age make a difference? Hypertension. 2004;44:631–6.PubMedCrossRef

93.

Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:487–99.PubMedCrossRef

94.

de Bruijn RF, Bos MJ, Portegies ML, Hofman A, Franco OH, Koudstaal PJ, et al. The potential for prevention of dementia across two decades: the prospective, population-based rotterdam study. BMC Med. 2015;13:132.PubMedPubMedCentralCrossRef

95.

Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6:e1000058.PubMedPubMedCentralCrossRef

96.

Shep Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (shep). JAMA. 1991;265:3255–64.CrossRef

97.

Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, et al. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384:1921–30.PubMedCrossRef

98.

Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet. 1997;350:757–64.PubMedCrossRef

99.

Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268–79.PubMedCrossRef

100.

Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315:2673–82.PubMedPubMedCentralCrossRef

101.

Yoon SS, Carroll MD, Fryar CD. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief. 2015:1–8.

102.

Gu A, Yue Y, Desai RP, Argulian E. Racial and ethnic differences in antihypertensive medication use and blood pressure control among us adults with hypertension: the national health and nutrition examination survey, 2003 to 2012. Circ Cardiovasc Qual Outcomes. 2017;10.

103.

Wang X, Poole JC, Treiber FA, Harshfield GA, Hanevold CD, Snieder H. Ethnic and gender differences in ambulatory blood pressure trajectories: results from a 15-year longitudinal study in youth and young adults. Circulation. 2006;114:2780–7.PubMedCrossRef

104.

Fumo MT, Teeger S, Lang RM, Bednarz J, Sareli P, Murphy MB. Diurnal blood pressure variation and cardiac mass in American Blacks and Whites and South African Blacks. Am J Hypertens. 1992;5:111–6.PubMedCrossRef

105.

Stevens J, Truesdale KP, Katz EG, Cai J. Impact of body mass index on incident hypertension and diabetes in Chinese Asians, American Whites, and American Blacks: the People’s Republic of China study and the atherosclerosis risk in communities study. Am J Epidemiol. 2008;167:1365–74.PubMedCrossRef

106.

Andrew ME, Jones DW, Wofford MR, Wyatt SB, Schreiner PJ, Brown CA, et al. Ethnicity and unprovoked hypokalemia in the atherosclerosis risk in communities study. Am J Hypertens. 2002;15:594–9.PubMedCrossRef

107.

Wright JT, Rahman M, Scarpa A, Fatholahi M, Griffin V, Jean-Baptiste R, et al. Determinants of salt sensitivity in black and white normotensive and hypertensive women. Hypertension. 2003;42:1087–92.PubMedCrossRef

108.

Sorlie PD, Allison MA, Avilés-Santa ML, Cai J, Daviglus ML, Howard AG, et al. Prevalence of hypertension, awareness, treatment, and control in the Hispanic Community Health Study/Study of Latinos. Am J Hypertens. 2014;27:793–800.PubMedPubMedCentralCrossRef

109.

Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016. NCHS Data Brief. 2017:1–8.

110.

Foti K, Wang D, Appel LJ, Selvin E. Hypertension awareness, treatment, and control in us adults: trends in the hypertension control cascade by population subgroup (national health and nutrition examination survey, 1999–2016). Am J Epidemiol. 2019;188:2165–74.PubMedPubMedCentralCrossRef

111.

Fuentes A, Ackermann RR, Athreya S, Bolnick D, Lasisi T, Lee SH, et al. Aapa statement on race and racism. Am J Phys Anthropol. 2019;169:400–2.PubMedCrossRef

112.

Leng B, Jin Y, Li G, Chen L, Jin N. Socioeconomic status and hypertension: a meta-analysis. J Hypertens. 2015;33:221–9.PubMedCrossRef

113.

Nachman D, Gilan A, Goldstein N, Constantini K, Littman R, Eisenkraft A, et al. 24-hour ambulatory blood pressure measurement using a novel non-invasive, cuff-less, wireless device. Am J Hypertens. 2021.

114.

National Center for Health Statistics (U.S.). Health US, 2013: With special feature on, prescription drugs. Hyattsville MNCfHS, (U.S.), 2014.

115.

Rodriguez CJ, Allison M, Daviglus ML, Isasi CR, Keller C, Leira EC, et al. Prevention AHACoEa, Cardiology AHACoC, Nursing AHACoCaS: Status of cardiovascular disease and stroke in Hispanics/Latinos in the United States: a science advisory from the American Heart Association. Circulation. 2014;130:593–625.PubMedPubMedCentralCrossRef

116.

Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.PubMedCrossRef

117.

Trial PHA. Major outcomes in high-Risk hypertensive patients. Jama. 2002;288(23):2981–97.

118.

Kim EJ, Kim T, Paasche-Orlow MK, Rose AJ, Hanchate AD. Disparities in hypertension associated with limited English proficiency. J Gen Intern Med. 2017;32:632–9.PubMedPubMedCentralCrossRef

119.

Johnson RL, Roter D, Powe NR, Cooper LA. Patient race/ethnicity and quality of patient-physician communication during medical visits. Am J Public Health. 2004;94:2084–90.PubMedPubMedCentralCrossRef

120.

Cené CW, Roter D, Carson KA, Miller ER, Cooper LA. The effect of patient race and blood pressure control on patient-physician communication. J Gen Intern Med. 2009;24:1057–64.PubMedPubMedCentralCrossRef

121.

Gerber LM, Mann SJ, McDonald MV, Chiu YL, Sridharan S, Feldman PH. Diuretic use in black patients with uncontrolled hypertension. Am J Hypertens. 2013;26:174–9.PubMedPubMedCentralCrossRef

122.

Fan AZ, Strasser SM, Zhang X, Fang J, Crawford CG. State socioeconomic indicators and self-reported hypertension among us adults, 2011 behavioral risk factor surveillance system. Prev Chronic Dis. 2015;12:E27.PubMedPubMedCentralCrossRef

123.

Mahajan S, Caraballo C, Lu Y, Valero-Elizondo J, Massey D, Annapureddy AR, et al. Trends in differences in health status and health care access and affordability by race and ethnicity in the united states, 1999–2018. JAMA. 2021;326:637–48.PubMedPubMedCentralCrossRef

124.

Tziomalos K, Giampatzis V, Baltatzi M, Efthymiou E, Psianou K, Papastergiou N, et al. Sex-specific differences in cardiovascular risk factors and blood pressure control in hypertensive patients. J Clin Hypertens (Greenwich). 2014;16:309–12.PubMedCrossRef

125.

Guirguis-Blake JM, Evans CV, Webber EM, Coppola EL, Perdue LA, Weyrich MS. Screening for hypertension in adults: updated evidence report and systematic review for the us preventive services task force. JAMA. 2021;325:1657–69.PubMedCrossRef

126.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. Members: ATF: 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. J Hypertens. 2018;36:1953–2041.PubMedCrossRef

127.

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334–57.PubMedCrossRef

128.

Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, et al. Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34:506–25.PubMedCrossRef

129.

Whelton PK, Appel L, Charleston J, Dalcin AT, Ewart C, Fried L, Kaidy D, Klag MJ, Kumanyika S, Steffen L, Walker WG. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention, phase I. Jama. 1992;267(9):1213–20.CrossRef

130.

The Trials Of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The trials of hypertension prevention, phase ii. Arch Intern Med. 1997;157:657–67.CrossRef

131.

Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (tone). JAMA. 1998;279:839–46.PubMedCrossRef

132.

Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA. 2009;302:401–11.PubMedPubMedCentralCrossRef

133.

He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35:544–9.PubMedCrossRef

134.

Stamler R, Stamler J, Gosch FC, Civinelli J, Fishman J, McKeever P, et al. Primary prevention of hypertension by nutritional-hygienic means. Final report of a randomized, controlled trial. JAMA. 1989;262:1801–7.PubMedCrossRef

135.

Takahashi Y, Sasaki S, Okubo S, Hayashi M, Tsugane S. Blood pressure change in a free-living population-based dietary modification study in Japan. J Hypertens. 2006;24:451–8.PubMedCrossRef

136.

Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. Committee NHBPEPC: Primary prevention of hypertension: clinical and public health advisory from the national high blood pressure education program. JAMA. 2002;288:1882–8.PubMedCrossRef

137.

Fisch IR, Frank J. Oral contraceptives and blood pressure. JAMA. 1977;237:2499–503.PubMedCrossRef

138.

Meade TW, Haines AP, North WR, Chakrabarti R, Howarth DJ, Stirling Y. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet. 1977;2:948–51.PubMedCrossRef

139.

Weir RJ, Briggs E, Mack A, Naismith L, Taylor L, Wilson E. Blood pressure in women taking oral contraceptives. Br Med J. 1974;1:533–5.PubMedPubMedCentralCrossRef

140.

Liu H, Yao J, Wang W, Zhang D. Association between duration of oral contraceptive use and risk of hypertension: a meta-analysis. J Clin Hypertens (Greenwich). 2017;19:1032–41.PubMedCrossRef

141.

American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122(5):1122–31.

142.

National Institutes of Health. Amendment. NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research. 2017. https://grants-nih-gov.yale.idm.oclc.org/grants/guide/notice-files/NOT-OD-18-014.html. Accessed 6 Jan 2022.

143.

Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.PubMedCrossRef

144.

Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY, Geller RJ, et al. Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol. 2018;71:1960–9.PubMedCrossRef

145.

Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women’s participation in cardiovascular clinical trials from 2010 to 2017. Circulation. 2020;141:540–8.PubMedCrossRef

Titel: Hypertension Across a Woman’s Life Cycle
verfasst von: Lama Ghazi
Rahul V. Annabathula
Natalie A. Bello
Li Zhou
Richard Brandon Stacey
Bharathi Upadhya
Publikationsdatum: 09.11.2022
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 12/2022
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-022-01230-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

Strategies to Improve Medication Adherence and Blood Pressure Among Racial/Ethnic Minority Populations: A Scoping Review of the Literature from 2017 to 2021

Effects of Hypertension on Alzheimer’s Disease and Related Disorders

Immune Cell Activation in Obesity and Cardiovascular Disease

Six Decades of History of Hypertension Research at the University of Toledo: Highlighting Pioneering Contributions in Biochemistry, Genetics, and Host-Microbiota Interactions

Antenatal Programming of Hypertension: Paradigms, Paradoxes, and How We Move Forward